newsfilter
← Latest News
GlobeNewswire·

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

--No safety issues identified in Cohort 1 ---- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled trial ---- Topline